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Resumo 
A insuficiência cardíaca afecta grande parte da população mundial de tal forma que 
é já considerada uma epidemia. Esta síndrome caracteriza-se por alterações estruturais e 
funcionais no coração, que passa a bombear o sangue de forma insuficiente. O estudo da 
progressão desta desordem cardíaca é portanto essencial e os estudos recentes visam 
identificar potenciais alvos terapêuticos que sejam mais eficazes. Recentemente, foi 
identificado um novo péptido chamado intermedina (IMD), cujos níveis de expressão estão 
aumentados em vários modelos de patologias cardíacas, incluindo hipertensão sistémica e 
isquemia. No entanto, o seu papel nestas patologias ainda não está completamente 
estabelecido.  
Assim, começamos por estudar o efeito miocárdico da IMD em dois modelos de 
insuficiência cardíaca induzida por sobrecarga de pressão: “TAC”, cuja sobrecarga resulta 
do aperto da aorta; o modelo que denominamos por “L-NAME”, cuja sobrecarga de 
pressão resulta da inibição da produção de óxido nítrico, por administração oral de L-
NAME, um inibidor das sintases de óxido nítrico. Nos seus respectivos controlos (“Sham” e 
“Ctrl”), a adição de IMD induziu um efeito inotrópico negativo. Apesar de semelhante em 
valor absoluto, o efeito da IMD nos modelos de doença foi totalmente oposto: verificamos 
um efeito inotrópico positivo acompanhado por um aumento da lusitropia. Ao nível basal, 
verificamos que os dois modelos de doença apresentam função sistólica inalterada, 
hipertrofia do ventrículo esquerdo e stress oxidativo aumentado. Ao nível proteico, 
verificamos que, nos controlos, a adição de IMD triplicou a quantidade de eNOS fosforilada 
no resíduo Ser-1177, sugerindo um aumento de actividade desta proteína. Além disso, 
também observamos um aumento da fosforilação da troponina I, possivelmente devida à 
activação da via de sinalização dependente de óxido nítrico e cGMP. Por outro lado, nos 
modelos de doença, verificamos que a fosforilação basal da eNOS estava aumentada e 
que a adição de IMD não alterou estes níveis. Verificamos, contudo, que houve um 
aumento da fosforilação da fosfolambam, possivelmente devida à activação da via de 
sinalização dependente de cAMP e PKA.  
Assim, mostramos pela primeira vez que a IMD induz efeitos opostos em 
miocárdios saudáveis e doentes, que se devem à incapacidade de a IMD aumentar a 
actividade da eNOS nos modelos de doença. Além disso, e dado que mecanismos 
distintos medeiam estes efeitos, este trabalho sugere que a disfunção endotelial cardíaca 
desempenha um papel preponderante na patofisiologia da insuficiência cardíaca por 
sobrecarga de pressão e, ao mesmo tempo, aponta a IMD como potencial marcador da 
disfunção endotelial cardíaca. 
 
Palavras-chave: insuficiência cardíaca, disfunção endotelial cardíaca, sintase endotelial de óxido nítrico, intermedina. 
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Abstract 
Heart failure affects many people around the world and then it is considered an 
epidemic. This syndrome is characterized by structural and functional changes in heart, 
which inefficiently pumps blood. The study of progression of this cardiac disorder is thus 
crucial and recent studies aim to identify potential and more effective therapeutic targets. 
Recently, a new peptide called intermedin (IMD) was identified, whose expression levels 
are augmented in several models of cardiac pathologies, such as systemic hypertension 
and ischemia. However, its role in these pathologies is not yet completely established. 
Therefore, we started to study myocardial effects of IMD in two heart failure models 
induced by pressure-overload: “TAC”, whose overload results from aortic banding; the 
model which we named as “L-NAME”, whose pressure-overload results from inhibition of 
nitric oxide production, by oral administration of L-NAME, an inhibitor of nitric oxide 
synthases. In their respective controls (“Sham” and “Ctrl”), addition of IMD elicited a 
negative inotropic effect. Despite being similar in absolute value, effect of IMD in diseased 
models was totally opposite: we verified a positive inotropic effect, allied to an increase of 
lusitropy. At the baseline, we observed these two diseased models present preserved 
systolic function, left ventricle hypertrophy and increased oxidative stress. At the protein 
level, in controls, IMD tripled content of phosphorylated eNOS at the Ser-1177, which 
suggest an increase of eNOS activity. Moreover, we also verified an increase of 
phosphorylation of troponin I, possibly due to activation of signaling pathway dependent of 
nitric oxide and cGMP. On the other hand, in diseased models, basal phosphorylated 
eNOS was increased and IMD did not alter those levels of phosphorylation. However, IMD 
elicited phosphorylation of phospholamban, eventually due to activation of cAMP/PKA 
signaling pathway.  
Thereby, we showed for the first time IMD induces opposite effects in healthy and 
diseased myocardium, which are due to inability of IMD to increase eNOS activity in these 
latter models. Besides, and given that distinct mechanisms mediate those effects, this work 
suggests cardiac endothelial dysfunction plays a preponderant role in pathophysiology of 
pressure-overload-induced heart failure and, at the same time, points IMD as a potential 
marker of cardiac endothelial dysfunction.   
 
 
 
Key words: heart failure, cardiac endothelial dysfunction, endothelial nitric oxide synthase, intermedin.  
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1. Heart Physiology 
 
 
1.1 Functional anatomy.  
Heart (Figure 1A) is a vital and muscular organ responsible for blood pumping 
to all body parts. Anatomically, it has four chambers: two auricles or atria, which are 
responsible for receiving blood, and two ventricles, whose main function is pumping 
blood. Heart is contained in a sac called pericardium, which is divided in fibrous and 
parietal pericardium. Next, there is the pericardial cavity containing the serous fluid and 
then there are the epicardium, the myocardium (composed entirely by muscle cells 
called cardiomyocytes) and endocardium (composed by endothelial cells). All these 
layers are illustrated in Figure 1B. The cardiac muscle is an involuntary contraction 
muscle with a type of response to a stimulus called “all-or-none response”.   
 
 
 
 
 
 
Figure 1 – A: Structure of the heart, from anterior perspective. B: Transversal section of the heart, showing its different 
layers. From http://www.guwsmedical.info/heart-failure/images/4415_27_47-pericardium-and-heart-wall.jpg .  
B 
A 
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Cardiomyocytes are short branching interconnecting cells, arranged as a 
syncytium, which is a multinucleated, protoplasmic mass of cells. In fact, myocardium 
functions like a syncytium since an applied stimulus in some part of the muscle results 
on contraction of whole muscle.  However, anatomically, myocardium is not considered 
a syncytium since effectively cardiomyocytes are separated from each other: laterally, 
by their cellular membranes (called sarcolemmas) and at their ends by dense 
structures called intercalated disks (Figure 2). These disks have gap junctions (Figure 
2), which facilitate the cardiac impulse conduction from a cell to another, and longer 
desmosomes (called fasciae adherens; Figure 2), which keep not only the 
cardiomyocytes together during contraction but also the normal electrical coupling 
between adjacent cardiomyocytes (Rasmussen, Palmfeldt et al., 2013).  
Cardiomyocytes contain a large number of mitochondria (called sarcossome; Figure 2) 
in order to allow a quick substrate oxidation and adenosine triphosphate (ATP) 
synthesis (Drago, De Stefani et al., 2012), which support the myocardial energetic 
requirements. In most species, each one of cardiomyocytes have two nuclei (Wright, 
Wu et al., 2012) (Figure 2) and, on average, each one is associated to one capilar, 
allowing a fast exchange and movement of important molecules between 
cardiomyocyte and capilar. This vascular network provides a suitable availability of 
oxygen and substrates in order to sustain the metabolic machinery.  
 
 
Figure 2 – Detailed view of disposition and structural composition of cardiomyocytes, showing gap juntions, 
desmossomes, intercalated discs, nucleus, sarcolemma, mitochondria and sarcoplasmic reticulum. From 
http://apbrwww5.apsu.edu/thompsonj/Anatomy%20&%20Physiology/2010/2010%20Exam%20Reviews/Exam%203%20
Review/18-11_AnatCardMusc.JPG 
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Inside cardiomyocytes, myofibrils are the contractile structures constituted by 
thousands of sarcomeres (Gregorio and Antin, 2000), which is defined as the section 
between two Z consecutive discs (Figure 3A). The sarcomere is divided into two main 
bands (Figure 3B): I band, which comprises the thin (actin) filaments segment which 
are not overlapped with thick (myosin) filaments; A band, which comprises the thick 
filaments, either those overlapped (zones of overlap) and those non-overlapped (H 
zone) with thin filaments. It’s because of those zones of overlap that cardiac muscle 
has a striated appearance (Cooper, 2000). The cross-connecting elements of 
cytoskeleton constitute the M line, which defines the middle line of the sarcomere 
(Figure 3A). As we can see in Figure 3B, thin and thick filaments are arranged in 
parallel (Krans, 2010). In addition to actin and myosin, sarcomere has other proteins 
such as titin and nebulin (Figure 3C), which are giant proteins that, among other 
functions, are responsible for protecting myofibrils when they are overstretched 
(Joseph, Stier et al., 2001) and for regulation of muscle contraction (Labeit, Ottenheijm 
et al., 2011). Troponin complex are another group of proteins of sarcomere, which is 
associated to tropomyosin and actin filaments and includes cardiac troponins I, C and 
T (cTnI, cTnC and cTnT). Particularly, cTnI is susceptible to be phosphorylated in its 
Threonine 144 (Thr-144), Serine 149 (Ser-149), Serine 43/45 (Ser-43/45) and Serine 
23/24 (Ser-23/24) residues (relatively to human sequence) (Layland, Solaro et al., 
2005). Phosphorylation of this latter is mediated by protein kinase A (PKA) and 
contributes for decreasing of myofilament Ca2+-sensivity (Kooij, Saes et al., 2010).   
 
 
 
 
A 
B 
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Figure 3 – A: Structure of a myofibril, showing its reference points (the M line and the Z discs) and the striated pattern 
of sarcomere. B: Detailed structure of a sarcomere, showing the titin filaments and the parallel alignment of thin (actin) 
and thick (myosin) filaments. Bands A and I, Z discs, M line and overlap and H zones are also represented. C: Protein 
composition of a sarcomere, showing tropomyosin, troponin complex (I, C and T), nebulin, C protein, myosin and titin. 
From http://www.revespcardiol.org/imatges/255/255v59n05/grande/255v59n05-13088668fig05.jpg and 
http://www.baileybio.com/plogger/images/anatomy___physiology/05._powerpoint_-_muscular_system/sarcomere.jpg . 
 
Myofibrils are surrounded by sarcoplasmic reticulum (SR; Figure 2), a small-
diameter sarcotubules network, which is responsible for storing intracellular Ca2+. Since 
its discovery, SR has always been touted as playing an important role in 
contraction/relaxation cycle (Fawcett, 1961), which was confirmed later. There is 
another tubular system inside cardiomyocytes which is composed by a large number of 
transversal tubules (T- tubules; Figure 4), which are invaginations of the sarcolemma 
into cardiomyocytes at the Z lines. This tubular system plays an important role in 
excitation-contraction coupling and provides to myofibrils and mitochondria a ready 
access to interstitial fluid.  
 
 
 
Figure 4 – Detailed view of cardiomyocyte, evidencing the T-tubular system. Adapted from 
http://www.courstudy.com/wp-content/uploads/2013/07/microscopic-anatomy-of-cardiac-muscle-sarcolemma-fasciae-
adherens-intercalated-discs-gap-junctions-t-tubules.jpg .  
C 
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1.2 Excitation-contraction coupling  
Muscular contraction (Figure 5) begins when an excitation wave spreads quickly 
along the sarcolemma and gap junctions and into cardiomyocytes via T-tubules. At 
sarcolemmal level, permeability to Ca2+ increases, leading to Ca2+ entering on the cell 
through sarcolemmal Ca2+ channels, called L-type Ca2+ channels (LTCC), whose 
channel proteins are phosphorylated by cAMP, and T-tubules. This extracellular Ca2+ is 
not sufficient to set off myofibrils contraction; indeed, it is just a trigger for Ca2+ 
releasing by SR, which augments free Ca2+ in cytoplasm. In turn, these Ca2+ ions bind 
to cTnC, forming a complex which interacts with tropomyosin, unlocking active sites 
between actin and myosin filaments. Then, myofibrils contract and systole occurs. At 
the end of systole, Ca2+ influx stops and SR is no more stimulated. Cyclic adenosine 
monophosphate (cAMP) promotes phospholamban phosphorylation (p-PLB), which 
stimulates ATP-dependent Ca2+ pump (placed on SR), resulting in pumping of Ca2+ into 
SR. Besides, cAMP also phosphorylates cTnI, inhibiting the binding of Ca2+ to cTnC. 
So, cTnI binds to actin, keeping actin/tropomyosin complex and preventing the myosin 
connecting to the actin (Gomes, Potter et al., 2002). Diastole occurs (Figure 5) and 
extracellular Ca2+ is removed from cytoplasm through a Na+/Ca2+ exchanger and an 
ATP-dependent Ca2+ pump, both localized on sarcolemma.    
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Systole and diastole mechanisms. Numbers indicate the succession of events responsible for cardiac 
contraction and relaxation.  
From http://faculty.pasadena.edu/dkwon/chapter%2014/Chapter%2014_cardiology_files/slide0059_image021.jpg . 
 
Action potential enters from adjacent cells. 
 Voltage-gated Ca2+ channels open. Ca2+ enters 
cell.  
Ca2+ induces Ca2+ release through ryanodine 
receptor-channels (RyR). 
 Local release causes Ca2+ spark. 
 Summed Ca2+ sparks create a Ca2+ signal. 
 Ca2+ ions bind to troponin to initiate contraction. 
 Relaxation occurs when Ca2+ unbinds from 
troponin. 
 Ca2+ is pumped back into the sarcoplasmic 
reticulum for storage. 
 ca2+ is exchanged with Na+. 
 Na+ gradient is maintained by the Na+/K+ 
ATPase.  
 
 
 
 
 
  

 
  
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2. Heart failure  
 
 
2.1 Definition and general considerations 
Heart failure (HF), also called congestive heart failure (CHF), is defined as a 
clinical syndrome characterized by both structural and functional alterations in heart 
(Francis and Tang, 2003). That condition incapacitates heart, thus it does not pump 
sufficient blood to all parts of body, leading to a multisystem disorder. Nowadays, heart 
failure is considered an epidemic disease, given that many people around the world 
suffer it: in fact, in Europe, it is the major cause of death (Figure 6).  This elevated rate 
is intimately associated with increased prevalence of risk factors, such as diabetes, 
hypertension and obesity (López-Sendón, 2011), arising from unhealthy lifestyles. 
While at the society it is increasingly important to raise awareness of the prevention of 
HF, at the scientific community there is an effort to unravel processes and mechanisms 
responsible for emergence and progression of heart failure.  
 
 
 
Figure 6 – Major causes of death in Europe. Cardiovascular disease is the major one in both genders. From 
http://www.micromedcv.com/eu/images/stories/major_causes_death_europe-big.jpg.   
 
 
Clinically, according the New York Heart Association (NYHA), progression of 
HF is divided into four different classes, characterized by severity of symptoms (Table 
1) and quality of life. 
 
 
FCUP 
Myocardial effect of Intermedin in hypertrophic heart:                                                                                    
mechanisms and involvement of endothelial dysfunction 
8 
 
Table 1 – Classification of heart failure and their respective symptomatology, according with the New York Heart 
Association. 
   
HF may assume two different forms, since it can result from a disability of the 
ventricles both contract normally (called heart failure with reduced ejection fraction or 
systolic heart failure, HFrEF) or relax completely during diastole (called heart failure 
with preserved ejection fraction or diastolic heart failure, HFpEF) (Borlaug and Paulus, 
2011; Gutierrez and Blanchard, 2004). Population studies have pointed out this latter 
dysfunction as the most popular among elderly people (Kitzman, 2000); moreover, 
HFpEF is considered a major cause of morbidity and mortality (Borlaug and Paulus, 
2011). Despite not having systolic dysfunction, these patients have a stiff heart due to 
fibrosis, resulting in a decreasing of diastolic filling. Hence, the amount of blood 
pumped is lower during systole (Kitzman, 2000). Given its importance and since its 
pathophysiology is not very well understood yet (Borlaug and Paulus, 2011), diastolic 
HF has been studied by many groups.  
 
 
2.2 Animal Models  
Although there is not an animal model able to completely mimic the human HF  
(Doggrell and Brown, 1998), investigators have tried to develop the best one. Currently, 
rat is the most used animal model since it presents numerous advantages, such as low 
costs and advanced technology, which has been optimized for this model (Patten and 
Hall-Porter, 2009).  However, this animal model also presents some limitations 
especially concerning its myocardial function, which differs from human in some 
aspects, such as the size of action potential (Hasenfuss, 1998). Regarding HF, there 
are many different rat models, depending on the primary reason for that failure and 
what the investigators want to study (Table 2) (Doggrell and Brown, 1998; Hasenfuss, 
1998). One of the most used models is the transverse aortic constriction (TAC), where 
HF results from a pressure overload-induced hypertrophy (Rockman, Ross et al., 
Class Patient Symptoms 
I (Mild) 
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
rapid/irregular heartbeat (palpitation) or shortness of breath (dyspnea). 
II (Mild) 
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity 
results in fatigue, rapid/irregular heartbeat (palpitation) or shortness of breath (dyspnea). 
III (Moderate) 
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity 
causes fatigue, rapid/irregular heartbeat (palpitation) or shortness of breath (dyspnea). 
IV (Severe) 
Unable to carry out any physical activity without discomfort. Symptoms of fatigue, 
rapid/irregular heartbeat (palpitation) or shortness of breath (dyspnea) are present at rest. 
If any physical activity is undertaken, discomfort increases.  
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1991). According to deAlmeida et al, TAC is a more faithful model of cardiac 
hypertrophy and resembles to human HF because of its gradual development 
(deAlmeida, van Oort et al., 2010). This model consists in constriction of aorta, 
resulting in a pressure-overloaded heart.  
 
Table 2 – Some rat models of hypertension, hypertrophy and heart failure. This table was adapted from Doggrell et al 
(Doggrell and Brown, 1998).    
Syndrome Model 
Hypertension 
 
 Systemic 
 Spontaneously Hypertensive Rats (SHRs) 
 Stroke-prone SHR (SHR-SP) 
 Mineralocorticoids (DOCA–salt) 
 NO synthase inhibition (L-NAME administration) 
 Transgenics (TGR(mREN2)27 rats) 
 Diabetic hypertensive rats (STZ-SHR, Zucker) 
o Renal o Renal artery occlusion (1K1C, 2K1C) 
 Pulmonary 
 Monocrotaline 
 Hypoxia (normobaric, hypobaric) 
Hypertrophy 
- Spontaneously Hypertensive Rats (SHRs) 
- Renal artery occlusion  
- Pressure loading (aortic banding)  
- Catecholamines (noradrenaline, isoprenaline)  
- Transgenics 
Heart failure 
 
 Systemic hypertension 
 Spontaneously Hypertensive Rats (SHRs-F)  
 Hypertensive HF prone rats  
 Dahl/Rapp salt-sensitive rats 
o Ischaemic heart failure o  Non-occlusive coronary ligation 
 Myocardial infarction 
 Coronary ligation 
  Microembolization of coronary vessels 
 Cardiomyopathy  Toxins (adriamycin, ethanol) 
o Myocarditis 
o Autoimmune  
o Chagas' disease 
 Pulmonary 
hypertension 
 Monocrotaline  
 Hypoxia 
 Miscellaneous  Aortacaval fistula (shunts) 
 
Another recognized pressure-overload model is L-NAME, which results from 
chronic administration of L-NAME (NG-nitro-L-arginine methyl ester, a nitric oxide 
synthase inhibitor) in drinking water, promoting systemic hypertension. This model is 
mostly used in human hypertension studies (Kopincova, Puzserova et al., 2012). Under 
these conditions, heart triggers a set of mechanisms resulting in molecular, cellular and 
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interstitial changes, through alteration of genomic expression (Cohn, Ferrari et al., 
2000). These, in turn, are responsible for alterations in shape, size and function of the 
heart (Cohn, Ferrari et al., 2000). This complex process was firstly described by Pfeffer 
et al (Pfeffer, Pfeffer et al., 1985) and after named cardiac or ventricular remodelling. In 
addition to pressure-overload, cardiac remodelling also occurs after myocardial 
infarction, myocarditis, idiopathic dilated cardiomyopathy and volume-overload (Mihl, 
Dassen et al., 2008), being associated to HF progression (Cohn, Ferrari et al., 2000). 
 
 
 
 
 
2.3 Progression 
A common type of cardiac remodelling is cardiac hypertrophy, a myocardial 
response to the intensification of workload, which aims to decrease the myocardial wall 
stress (Czubryt and Olson, 2004; Grossman, Jones et al., 1975; Kehat and Molkentin, 
2010). In literature, there are considered two distinct types of hypertrophy: the 
physiological one, which runs from healthy exercise or pregnancy and where 
myocardial integrity is maintained (Kehat and Molkentin, 2010); the pathological one, 
which comprises the growth (in size) of cardiomyocytes and the “turn on” of the foetal 
genetic program (Frey, Katus et al., 2004). Besides, expression of proteins relevant for 
excitation/contraction coupling is altered as well as energetic and metabolic states of 
cardiomyocytes.  
Macroscopically, the pressure overload, achieved by hypertension or aortic 
stenosis, leads to increase of cardiomyocyte width rather than length which is due to 
addition of sarcomeres in parallel (Lorell and Carabello, 2000). This results in an 
increased wall thickness/chamber dimension ratio (Lorell and Carabello, 2000), which 
results in impairment of cardiac function (Moorjani, Catarino et al., 2003). This 
hypertrophy is called concentric (Figure 7) and it is also characterized by an enhanced 
contractile protein synthesis (Carabello, 2002; Imamura, McDermott et al., 1994). In 
contrast, volume overload promotes addition of sarcomeres in series (Morgan and 
Proske, 2004), leading to growth of cardiomyocytes in length rather than width and 
increasing the internal radius of ventricle (Kehat and Molkentin, 2010). This 
hypertrophy is commonly called eccentric hypertrophy (Figure 7).  
 
 
 
 
FCUP 
Myocardial effect of Intermedin in hypertrophic heart:                                                                                    
mechanisms and involvement of endothelial dysfunction 
11 
 
 
Figure 7 – Concentric and eccentric cardiac hypertrophy. These two different types of pathological hypertrophy are 
geometrically different due to different addition of sarcomeres inside cardiomyocytes. Adapted from Maillet et al (Maillet, 
van Berlo et al., 2013).  
 
 
It is believed pathological hypertrophy is, initially, a compensatory mechanism 
which often results in a decompensated stage. For this transition, there are some 
important players, such as increase of fibrosis (Czubryt and Olson, 2004), which is 
characterized by an elevated deposition of collagens and other extracellular matrix 
(ECM) components. According Jalil et al this accumulation is responsible for increasing 
of cardiac muscle stiffness and decreasing of ventricular compliance (Jalil, Doering et 
al., 1989).  Another crucial player in that transition is decreasing of the number of 
cardiomyocytes through apoptosis, necrosis and autophagy (Dorn, 2009). Finally, 
Mancia et al suggested neurohumoral activation plays an important role in that process 
of transition since it is very increased in HF (Mancia, 1990). 
 
 
2.3.1 Neurohumoral activation 
This activation comprises a subsequent chronic activation of both sympathetic 
nervous (Triposkiadis, Karayannis et al., 2009) and renin-angiotensin-aldosterone 
(Unger and Li, 2004) systems (SNS and RAAS, respectively) which under physiologic 
conditions results in an increase of heart rate, myocardial inotropy, vasoconstriction 
and blood volume (Jackson, Gibbs et al., 2000) (Figure 8A). However, under 
pathological conditions (Figure 8B), SNS hyperactivation leads to a chronic release of 
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catecholamines, resulting not only in increase of permeability of sarcolemma, Ca2+ 
overload and potential increase in cardiomyocyte death (Opie, Commerford et al., 
2006), but also in chronic stimulation of beta-adrenergic receptors (β-ARs), which are 
localized at the sarcolemma. In HF, β1-ARs are downregulated while β2-ARs are 
uncoupled (Ahmed, 2003). Besides, β-ARs kinase (BARK) phosphorylates both β1- 
and β2-ARs, contributing for their desensitization (Freedman and Lefkowitz, 1996). 
Interestingly, β3-AR is upregulated in the progression of HF (Moniotte, Kobzik et al., 
2001) and recently was identified as a potential and promising new target for 
therapeutics since its stimulation in vivo contributed for protective mechanisms in 
pressure-overloaded mice (Niu, Watts et al., 2012).  
 
 
 
 
 
A 
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 Figure 8 – Effects of neurohumoral activation under physiologic (A) and pathological (B) conditions. In both situations, activation of SNS and RAAS is involved but has different 
effects. Dashed arrows indicate chronic effect. AM means adrenomedullin; IMD means intermedin. This figure was done using Servier Medical Art.  
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Activation of RAAS, in turn, leads not only to the rise of renin and aldosterone 
but also plasma levels of angiotensin II, which increases cytosolic Ca2+ (Chen, Zhang et 
al., 2005) and reactive oxygen and nitrogen species (ROS and RNS, respectively) 
generation, contributing to cell death (Opie, Commerford et al., 2006). Additionally, it 
promotes transforming growth factor β (TGF-β) expression, enhancing fibrosis (Peng, 
Carretero et al., 2005). Therefore, pathological neurohumoral activation via SNS and 
RAAS culminate in elevated myocardial wall stress, worsening of hypertrophy, 
imbalance between oxygen demand and supply, increasing of contractility and 
damaging of cardiomyocytes (Jackson, Gibbs et al. 2000) (Figure 9). 
 
 
 
 
 
 
 
 
 
Figure 9 – Effects of neurohumoral activation, mediated by SNS and RAAS, on heart structure and function. 
 
In addition to angiotensin-II, other neurohormones are augmented in HF (Figure 
8B). One of them is endothelin-1 (McMurray, Ray et al., 1992), which is synthetized by 
endothelial cells (Zolk and Bohm, 2000) and its plasma levels indicate severity of HF 
(Spinarova, Spinar et al., 2004). It is a potent vasoconstritor partially due to prevention 
of nitric oxide (NO) production, through stimulation of asymmetric dimethylarginine 
(ADMA), which is a NO synthase (NOS) inhibitor (Ohnishi, Wada et al., 2002).  
Similarly, adrenomedullin (AM) is produced by endothelial cells and its plasma levels 
are correlated with severity of HF, in terms of its hemodynamic dysfunction (Nicholls, 
Charles et al., 2003). It has a potent vasodilator effect and its systemic infusion seems 
to have a beneficial effect in HF (Ishimitsu, Ono et al., 2006). Conversely, urotensin-II 
plasma levels are not so informative and is thought as being a local paracrine or 
autocrine mediator (Kruger, Graf et al., 2005). Concerning intermedin (IMD), its 
cardiovascular effects are described in the third section.  
Neurohumoral activation also stimulates release of natriuretic peptides (Figure 
8B) whose effects are targeted at heart, kidneys and central nervous system (Jackson, 
Gibbs et al., 2000). These hormones include atrial and brain natriuretic peptides, which 
Neurohumoral 
activation 
 
   Myocardial stress 
   Hypertrophy 
Imbalance oxygen demand/supply 
   Contractility 
   Damaging of cardiomyocytes 
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are originated from myocardial cells, C-type natriuretic peptide, which is secreted by 
endothelial cells, and urodilatin, which is thought to be secreted by kidney (Chen and 
Burnett, 2006). All these peptides mediate vasodilator effects and promote both 
natriuresis and diuresis (Almenar Bonet and Martinez-Dolz, 2006), thereby 
counteracting the effects of RAAS (de Sa and Chen, 2008). Therefore, exogenous 
administration of these peptides emerged as an efficient therapeutic in patients with HF 
(de Sa and Chen, 2008). Another theoretical way to enhance natriuretic peptides 
plasma levels consists in inhibiting the neutral endopeptidase (NEP), since this one is 
responsible for the metabolism of natriuretic peptides (Klabunde, 2011). Despite its 
beneficial effects, this therapeutic showed no effectiveness in all HF patients. 
Therefore, current investigation aims to design a more effective therapeutic for 
widespread use. Recently, treatment using a combination of NEP inhibitors with 
angiotensin-II blockers showed promising results (Cuculi and Erne, 2011).  
 
 
2.3.2 Cytokines 
HF is also an inflammatory syndrome (Blum and Miller, 1998) involving a set of 
mechanisms and agents which includes the tumor necrosis factor-α (TNF-α) and 
interleukins 2, 6 and 1β (IL-6, IL-2 and IL-1β) (Mehra, Ramgolam et al., 2005). It is 
thought that a desiquilibrium between proinflammatory and anti-inflammatory agents 
could partly explain myocardial damage and progression of HF (Oikonomou, Tousoulis 
et al., 2011). Evidence shows proinflammatory cytokines are produced by 
cardiomyocytes (Aoyagi and Matsui, 2011) and have a biphasic cardiac response 
(Mehra, Ramgolam et al., 2005). Endothelial and systolic dysfunctions, myocardial 
hypertrophy, activation of foetal gene program and fibrosis are some of their cardiac 
effects (Oikonomou, Tousoulis et al., 2011). However, proinflammatory citokines also 
have extra-myocardial effects, for example at the bone marrow, where they are able to 
affect erythropoiesis (Okonko and Anker, 2004).   
 
2.3.3 Matrix Metalloproteinases 
Until now, it was thought ECM worked only as a support for cardiomyocytes and 
blood vessels, in heart. However, recent evidence has shown ECM has a dynamic 
complexity (Brown, 2005) and plays an important role in progression of HF (Miner and 
Miller, 2006) since increased deposition of its major component, collagen, leads to 
cardiac fibrosis (Zannad and Radauceanu, 2005). Other important components of ECM 
include a group of 24 endopeptidases called matrix metalloproteinases (MMPs) and 
their tissue inhibitors (TIMPs) (Miner and Miller, 2006). Metalloproteinases are 
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responsible for degradation and removal of ECM molecules (Nagase, Visse et al., 
2006). In pigs with HF, MMPs abundance and activity are increased (Coker, Thomas et 
al., 1998); furthermore, under those conditions also TIMPs levels are altered, resulting 
in an imbalance between these two protein families (Moore, Fan et al., 2012). Hence, 
both MMPs and TIMPs are promising therapeutic targets for discovery of new drugs, 
which could be more effectively in treatment of HF (Li, McTiernan et al., 2000).  
 
2.3.4 Oxidative stress 
Evidence has also demonstrated that in HF, oxidative stress, defined as an 
imbalance between ROS/RNS produced and cellular antioxidant capacity (Thannickal 
and Fanburg, 2000), is augmented and accompanied by an antioxidant deficit (Belch, 
Bridges et al., 1991; Hill and Singal, 1996; Hill and Singal, 1997; Mallat, Philip et al., 
1998). Despite playing an important role in many biological cellular processes (Anathy, 
Roberson et al., 2012; Hancock, Desikan et al., 2001; Martinez and Andriantsitohaina, 
2009; Simon, Haj-Yehia et al., 2000), both ROS and RNS cellular accumulation is 
deleterious. To the molecular level, oxidative stress is responsible for damaging of 
nucleic acids, lipids, proteins and other macromolecules (Martinez and 
Andriantsitohaina, 2009; Thannickal and Fanburg, 2000) however, it can also promotes 
specific, reversible/irreversible oxidative modifications on proteins, altering their activity 
or function (Finkel and Holbrook, 2000).  
Within the heart, cardiomyocytes, endothelial cells and neutrophils are sources 
of ROS, but inside each cardiomyocyte there are many different sources responsible 
for that production, namely mitochondria, nicotinamide adenine dinucleotide phosphate 
(NADPH) and xanthine oxidases and uncoupled NOS (Bevers, Braam et al., 2006; 
Tsutsui, Kinugawa et al., 2011) (Figure 10). Concerning mitochondria, recent data 
shows progression of HF is associated with a progressive loss of respiratory activity of 
mitochondria, decreasing ATP production and jeopardising cellular processes 
responsible for cardiac pump function (Huss and Kelly, 2005). Many differences have 
been discovered between mitochondria from normal and failing hearts, either at 
morphologic, functional and biochemical levels (Abel and Doenst, 2011; Rosca and 
Hoppel, 2010). Curiously, despite being a source of ROS, mitochondria are severely 
affected by them since ROS are responsible for mitochondrial DNA damage (Tsutsui, 
Kinugawa et al., 2011). Recently, also endothelial dysfunction was indicated as a 
potential strong contributor for pathophysiology and progression of HF (Lam and 
Brutsaert, 2012) and is also associated with HF severity (Marti, Gheorghiade et al., 
2012). Given that and since endothelial dysfunction results from an imbalance between 
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NO and ROS production (Bauersachs and Schafer, 2004) and endothelial NOS 
(eNOS) is the most abundant form of NOS expressed in endothelium (Balligand, Feron 
et al., 2009), namely endocardial endothelium (Kelly, Balligand et al., 1996), eNOS 
might play a central role in endothelial dysfunction and therefore in progression of HF. 
Accordingly, some authors have reported the potential protective role of endothelium-
derived NO in HF and other cardiac dysfunctions, such as arrhythmia (Albrecht, 
Stegeman et al., 2003; Burger and Feng, 2011; Fischer, Rossa et al., 2005; Nishida, 
Yu et al., 2009).  
 
 
 
Figure 10 – NADPH oxidase as the major source of ROS, under different stimuli including pressure-overload. Also 
mitochondria, xanthine oxidase and eNOS are sources of ROS, which contribute for an increasing of ROS/antioxidants 
(AO) ratio, resulting in oxidative stress. This redox cellular imbalance leads to heart failure, through a set of ROS-
mediated alterations including apoptosis and dysfunction of cardiomyocytes, fibrosis and hypertrophy. From Ocatavia et 
al (Octavia, Brunner-La Rocca et al., 2012).  
 
 
Thus, understand how eNOS works and is regulated under both physiologic and 
pathophysiologic conditions will be an important help for discovering of new efficient 
therapeutic targets.  
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2.3.4.1 eNOS 
Endothelial NOS is constitutively expressed by endothelial cells and belongs to 
a family of enzymes called nitric oxide synthases (NOSs), which are responsible for NO 
synthesis (Stuehr, 1999). This family also comprises two other NOS isoforms: neuronal 
and inducible NOS, nNOS and iNOS respectively (Stuehr, 1999). In heart, both eNOS 
and nNOS are constitutively expressed by cardiomyocytes while iNOS is only 
expressed after an inflammatory stimuli (Mount, Kemp et al., 2007). Structurally, eNOS 
has an N-terminal oxygenase domain containing binding domains to heme, L-arginine 
and tetrahydrobiopterin (BH4), a central region enabling calmodulin (CaM) binding and 
finally a C-terminal reductase domain containing binding sites to NADPH, flavin 
adenine dinucleotide (FAD) and flavin mononucleotide (FMN) (Stuehr, 1997) (Figure 
11). Endothelial NOS active form is an homodimer; however, since eNOS depends 
primarily on Ca2+/CaM presence (Rafikov, Fonseca et al., 2011), it should indeed be 
considered a tetramer (Alderton, Cooper et al., 2001). eNOS synthetizes NO and L-
citrulline from substrate L-arginine, requiring molecular oxygen, its dimer form and the 
cofactors: BH4, haem, FAD, FMN, CaM and NADPH (Forstermann and Munzel, 2006; 
Marletta, 1993). The cofactor BH4 is essential for eNOS normal function (Alp and 
Channon, 2004): decreasing of BH4 bioavailability, either by its oxidation or reduction of 
its synthesis, results in uncoupling of eNOS (Moens and Kass, 2006). Besides, BH4 is 
responsible for dimer stabilization and increase of substrate affinity of NOS, and has 
some antioxidant effects through scavenging of NO-derived RNS and ROS (Moens, 
Kietadisorn et al., 2010). Despite its exogenous administration was shown to be 
beneficial for cardiac function, BH4 has potential limitations in clinical use (Moens, 
Ketner et al., 2011).  
 
 
  
 
Figure 11 – Endothelial NOS structure, showing its oxygenase and reductase domains and its CaM binding site. This 
protein is able to be phosphorylated at tyrosine (Y), threonine (T) and serine (S) residues, which are numbered. Other 
modifications include myristoylation (M), palmitoylation (P), S-glutathionylation (G) and S-nitrosylation (N). Adapted from 
May (May, 2012). 
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De novo synthesis of BH4 is limited by guanosine triphosphate cyclohydrolase 1 
(GTPCH1), whose transcription (Katusic, Stelter et al., 1998; Linscheid, Schaffner et 
al., 1998), activity (Werner-Felmayer, Werner et al., 1993) and phosphorylation 
(Lapize, Pluss et al., 1998) are controlled by several citokines, angiotensin-II and 
platelet-derived growth factor. Degradation of GTPCH1 was reported in cardiovascular 
diseases (Moens, Kietadisorn et al., 2010; Zhao, Zhu et al., 2012), such as diabetes 
mellitus (Xu, Wu et al., 2007) and hypertension (Xu, Wang et al., 2009).   
In addition, eNOS expression itself is regulated at transcriptional and post-
transcriptional levels (Balligand, Feron et al., 2009; Searles, 2006). This latter includes 
posttranslational modifications such as S-nitrosylation, S-glutathionylation, binding of 
CaM, palmitoylation, acylation and phosphorylation (Chen, Wang et al., 2010; 
Dudzinski and Michel, 2007). Particularly, eNOS contains many potential 
phosphorylation sites such as tyrosine, serine and threonine residues (Alderton, 
Cooper et al., 2001) (Figure 11). Their phosphorylation regulates NO production, 
depending on not only residues type but also residue per se (Fulton, Church et al., 
2005; Li, Ruan et al., 2007; Ritchie, Kohlhaas et al., 2010; Ruan, Torres et al., 2011). 
Another regulatory mechanism of NO production by eNOS include protein-protein 
interactions: for instance, the binding of heat shock protein 90 (Hsp90) to eNOS is 
needed for Akt (also called PKB)-mediated phosphorylation of eNOS at Ser-1177 
(using the human sequence nomenclature) (Mount, Kemp et al., 2007) while the 
binding of caveolin-1 to eNOS is responsible for its inactivation (Ju, Zou et al., 1997). 
Also subcellular localization is important for eNOS activity (Sullivan and Pollock, 2003). 
At the baseline, eNOS is associated with plasma membrane (Church and Fulton, 2006) 
mainly due to its myristoylation (Busconi and Michel, 1993; Michel, 1999). However, in 
hypertensive rats, which present endothelial dysfunction, authors verified eNOS 
translocation from membrane to cytosol, suggesting that eNOS translocation may 
contribute for decreasing of NO bioavailability and thus for worsening of endothelial 
dysfunction and subsequently hypertension (Sullivan, Pollock et al., 2002).  
As stated above, in the failing heart there is an overproduction of ROS from 
various sources. Particularly, generated ●O2
- react with NO to form peroxynitrite 
(ONOO-), which then oxidizes BH4 (Balligand, Feron et al., 2009), diminishing its 
bioavailability. Consequently, eNOS suffers an enzymatic change through alteration of 
its dimer architecture as well as its catalytic activity, leading to the synthesis of ●O2
- 
and/or hydrogen peroxide in vitro (Moens and Kass, 2006) and eventually to the direct 
production of ONOO- (Balligand, Feron et al., 2009). This production of ●O2
- instead of 
NO is commonly designated as uncoupling of eNOS (Forstermann and Munzel, 2006; 
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Massion, Feron et al., 2003). At the protein level, ONOO- reacts with tyrosine, 
generating 3-nitrotyrosine, which can be detected by specific antibodies (Daiber and 
Munzel, 2012). Indeed, nitrotyrosine is referred as a marker of both ONOO- formation 
and presence of oxidative stress (Sun, Carretero et al., 2005). Accordingly, its levels 
are increased in CHF patients (Hryniewicz, Yasskiy et al., 2004).  
Endothelial NOS-derived NO is thought to be coupled to cyclic guanosine 
monophosphate/protein kinase G (cGMP/PKG) pathway (Hammond and Balligand, 
2012). Activation of PKG is able to promote phosphorylation of various proteins such 
as PLB, LTCC and cTnI (Tsai and Kass, 2009).   
 
 
 
 
 
Throughout this 2.3 section, we mentioned some of the reasons that explain the 
transition between the compensated state and HF. However, for now, other 
mechanisms and intervenients are still under exhaustive study and investigators 
continue to search for answers (Kehat and Molkentin, 2010). Next years, this so 
complex transition could be more highlighted, bringing new potential and more efficient 
therapeutic targets.     
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3. Intermedin 
The calcitonin/calcitonin gene-related peptide (CGRP) family peptide includes 
peptides such as calcitonin, CGRP, amylin and AM (Chang, Roh et al., 2004). But in 
2004, the number of members of this family augmented, when a new peptide – IMD – 
was independently discovered by two distinct groups (Roh, Chang et al., 2004; Takei, 
Hyodo et al., 2004). It is for that reason IMD is also known as AM2. The human IMD 
preprotein is constituted by 148 amino acids (preproIMD) but, through proteolytic 
cleavage at the N-terminus and amydation of C-terminus (Yang, Jia et al., 2005), it is 
able to generate two distinct mature forms constituted by 47 (IMD1-47 or IMDL) (Bell and 
McDermott, 2008) or 40 amino acids (IMD8-47 or IMDS). In addition, it is thought there is 
another IMD form with 53 amino acids (IMD1-53) resultant from cleavage of preproIMD 
at the Arginine 93-Argine 94 sites (Yang, Jia et al., 2005). Eventually, IMD1-53 would be 
degraded endogenously but might have an important bioactive action (Yang, Jia et al., 
2005). Alignment of mature IMD1-47 shows that human and rodent aminoacid 
sequences are 87% identical (Roh, Chang et al., 2004) (Figure 12).  
 
 
 
Figure 12 – Alignment of amino acids of IMD long form (IMD 1-47) from human (hIMD), mouse (mIMD) and rat (rIMD). 
Adapted from Roh et al (Roh, Chang et al., 2004). 
 
 
IMD is distributed all over the mammalians body, namely kidneys, 
gastrointestinal tract, brain, lungs, spleen, ovaries, pituitary, among many others 
(Takahashi, Morimoto et al., 2011). In rat heart, IMD is found in cardiomyocytes, with 
greater levels are found in those neonatal when compared with adult ones (Pan, Yang 
et al., 2005), which suggests IMD plays an important role during embryonic 
development (Bell and McDermott, 2008).  
The biological actions of IMD are mediated by three different receptors, which 
are heterodimers constituted by a calcitonin receptor-like receptor (CRLR) and one of 
the three receptor activity-modifying proteins (RAMP1-3) (Naot and Cornish, 2008). 
Moreover, these RAMP proteins are essential for ligand selectivity since CRLR alone 
shows a decreased affinity to its ligands (Pfeil, Aslam et al., 2009). The CRLR/RAMP1 
complex (or CGRP receptor) forms the CGRP receptor while the CRLR/RAMP2-3 
complexes (also called AM1 and AM2 receptors, respectively) form the AM receptors 
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(Hay, Walker et al., 2011). IMD binds non-specifically to all three CRLR/RAMP 
complexes (Takahashi, Morimoto et al., 2011). Despite that, there is a degree of 
binding affinity (Figure 13), since, for example, AM is also capable to bind to CGRP 
receptor (Zhao, Bell et al., 2006).  
 
 
 
Figure 13 – Binding affinity of CGRP, AM and IMD (AM2) to CGRP, AM1 and AM2 receptors and their constitution. Light 
grey cylinders represent calcitonin receptor-like receptor (CRLR). ECD means extracellular domain; TM means 
transmembrane; ICD means intracellular domain. Adapted from Hay et al (Hay, Walker et al., 2011). 
 
3.1 Cardiovascular effects  
Concerning cardiovascular effects, IMD1-47 elicits an increased heart rate in rat 
mediated by activation of SNS (Taylor, Bagley et al., 2005). Besides, its intravenous 
administration promotes a negative inotropic action suggested by a decline of blood 
pressure (Bell and McDermott, 2008). However, a positive inotropic effect elicited by 
IMD1-53 and IMD1-47 was reported both in isolated perfused heart from rat (Yang, Jia et 
al., 2005) and ventricular cardiomyocytes from mouse (Dong, Taylor et al., 2006), 
respectively. This apparent contradiction was recently clarified by Pires et al, who 
established a negative inotropic effect of IMD on myocardium, using rat left ventricular 
(LV) papillary muscles (Pires, Pinho et al., 2012).  Since AM also has different inotropic 
actions, dependent on both species and methodology used (Fontes-Sousa, Pires et al., 
2009; Ihara, Ikeda et al., 2000; Ikenouchi, Kangawa et al., 1997; Szokodi, Kinnunen et 
al., 1998), these evidences show and reinforce the complex biological action of 
members of this peptide family.  
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Behind IMD myocardial effects, there is a set of signalling pathways, 
messengers and mediators involved. However, there is no direct evidence proving that 
and conclusions have often been drawn by extrapolating of data from other members 
of this peptide family and from studies about IMD vascular effects. Nevertheless, it is 
thought IMD negative inotropic effect and vasodilator action is endothelium-dependent 
and mediated by NO/cGMP pathway, whereas positive inotropic effect is mediated by 
cAMP/PKA pathway (Burak Kandilci, Gumusel et al., 2006; Dong, Taylor et al., 2006; 
Pires, Pinho et al., 2012). But most importantly, IMD is now recognized as a potential 
important peptide in cardiac pathology since its expression levels are much greater in 
several models of failing hearts than in healthy ones (Bell, Zhao et al., 2008; Hirose, 
Totsune et al., 2008; Zeng, Yuan et al., 2009; Zhang, Jiang et al., 2009; Zhao, Bell et 
al., 2006). Furthermore, some studies have reported the potential protective role of IMD 
(Holmes, Campbell et al., 2013) as for example in prevention of myocardial apoptosis 
mediated by mitochondria via Akt/glycogen synthase kinase 3 beta (GSK-3β) signalling 
pathway (Song, Teng et al., 2009) and induction of autophagy of cardiomyocytes via 
cAMP/PKA and mitogen-activated protein kinases/extracellular signal-regulated 
kinases (MAPK/ERK) signalling pathways, preventing both apoptosis and hypertrophy 
of cardiomyocytes (Chen, Wang et al., 2013). Nevertheless, there is much work to do 
in order to explain the pathophysiologic impact of the augmented levels of IMD.  
 
 
4. Aims 
The general goal of this thesis was to study the myocardial response to IMD in 
chronic pressure-overloaded rats, its intracellular mechanisms and impact of cardiac 
endothelial dysfunction. 
In order to facilitate the understanding of the work, we divided it into three 
different points: 
1) To clarify and show differences between the two well-known pressure-overload 
models TAC and L-NAME, regarding their morphometric, haemodynamic and 
contractile parameters. 
2) To study myocardial effects of IMD in both control and pressure-overload 
animal models and unveil the potential intracellular signalling pathways 
involved. 
3) To investigate the influence of eNOS in differential response of myocardium to 
IMD. 
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1. Ethical approval 
The animal handling and experiments were performed in accordance with 
Portuguese law animal welfare and conform to the guidelines established by the 
Faculty of Medicine of the University of Porto (Porto, Portugal), animal welfare 
committee and principles of UK regulations, as described by Drummond (Drummond, 
2009).   
 
2.  Animals 
2.1 TAC rats   
Transverse aortic constriction (TAC) was performed similarly to Litwin et al  (Litwin, 
Katz et al., 1995). Seven weeks-old male Wistar-Han rats (Rattus norvegicus) were 
anesthetized with sevoflurane (2%) and placed on a temperature-controlled surgical table. 
After tracheal intubation, rats were connected to a rodent ventilator (Topo, small animal 
ventilator, Kent Scientific). A small incision at the level of the second left intercostal space 
was performed, the different muscle layers were cut and thoracic cavity was accessed. 
After identification and isolation of the aortic arch, a 3-0 non-absorbable silk suture was 
placed around aorta between the brachiocephalic and left carotid arteries (Figure 14) and 
tied together with a 25G needle, in order to standardize the constriction. After tying the 
suture, the needle was immediately removed to produce an aorta with a stenotic lumen. 
Then the thoracic cavity was closed using a 4-0 polypropylene suture, all layers of muscle 
were repositioned and skin was closed with 4-0 silk suture (TAC, n=14). The control 
animals are called “Sham” and they were subjected to a similar surgery without the 
tightening of aorta (Sham, n=12). Twenty one weeks after surgery, rats underwent 
hemodynamic evaluation or papillary muscles protocols, as described in Figure 15A.  
 
 
Figure 14 – Diagram of aorta adapted from an online quiz (http://quizlet.com/14064108/mini2-anatomy-flash-cards/). 
The blue boxes identify the brachiocephalic and left common carotid arteries and the black line in arch of aorta 
represents the local of the constriction.  
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2.2 Chronic deficiency of NO: L-NAME rats  
Seven weeks old male Wistar-Han rats (Rattus norvegicus) received the NOS 
inhibitor L-NAME in drinking water, in a concentration of 35 mg/kg/day for 10 weeks (L-
NAME, n=9), as previously described (Zhao, Bell et al., 2006). The control animals are 
called “Controls” (Ctrl) and they followed the same protocol except addition of L-NAME 
to their drinking water (Controls, n=11). Once completed the 10 weeks, rats underwent 
hemodynamic evaluation or papillary muscles protocols, as described in Figure 15B.  
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TAC (n=14) 
For hemodynamics evaluation: 
Sham (n=6) 
TAC (n=7) 
 For papillary muscles protocols: 
Sham (n=6) 
TAC (n=7) 
 
Sham (n=12) 
Birth 7-old weeks 28-old weeks 
Birth 7-old weeks 17-old weeks 
Water 
 
 Ctrl (n=11) 
For hemodynamics evaluation: 
Ctrl (n=5) 
L-NAME (n=4) 
 For papillary muscles protocols: 
Ctrl (n=6) 
L-NAME (n=5) 
 
Water 
+ 
L-NAME 
 L-NAME (n=9) 
B 
A 
Figure 15 – Schematic representation of how different rat models were obtained: A, Sham and TAC; B, 
Ctrl and L-NAME. Timelines represent the age of rats and black spots have a vertical matching with 
treatments or protocols made in that age.    
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3. LV hemodynamics evaluation  
The thoracic cavity was accessed and a 1.4Fr microtip pressure-volume (P-V) 
catheter (SPR-838, Millar Instruments) (externally calibrated and balanced with MPV-
300 Millar control unit) was inserted through an apical puncture wound into the LV 
cavity. Before insertion in LV, the catheter was immersed in distilled water bath at 37ºC 
for 30 minutes and was connected to MVPS-300 conductance system (Millar 
Instruments), coupled to a PowerLab16/30 converter (AD Instruments) and a personal 
computer for data acquisitions. After 10 minutes of stabilization, data were recorded 
continuously, in mmHg and units of conductance (RVU-relative volume units). At the 
end of protocol, rats were euthanized with intraperitoneal injection of sodium 
pentobarbital (200 mg/kg). Then, the heart was excised, weighed and myocardial 
samples collected for molecular and histologic studies.  
 
4. Isolated papillary muscles experiments  
Rats were anesthetized with intraperitoneal injection of 20% sodium 
pentobarbital (1mL/kg) and it was performed a total thoracotomy. Beating hearts were 
quickly excised and immersed in a serum solution (containing 5% Newborn Calf Serum 
and modified Krebs-Ringer (KR) solution composed by: 115 mM NaCl, 12 mM glucose, 
22 mM NaHCO3, 5,3 mM KCl, 1,2 mM NaH2PO4H2O, 0,99 mM MgCl26H2O, 1,2 mM 
CaCl22H2O), where ejection of blood was promoted. Then, muscles were put on BDM 
solution (which is similar to serum solution with addition of 0,3% cardioplegic 2,3-
butanedione monoxime (BDM)). The time from thoracotomy to dissection of papillary 
muscles was about 3 minutes. Muscles were dissected using a dissecting microscope 
in a 30ºC bath containing BDM solution. The LV was opened and papillary muscles 
were isolated first by dividing the chordae tendinae at the muscle tip and then freeing 
the muscle base and a small amount of surrounding myocardium from the ventricular 
wall. Only long, thin, uniformly cylindrical muscles were used. After dissection, papillary 
muscles were vertically mounted in a 10ml plexi glass organ bath (Figure 16), firstly 
containing the BDM solution at 30ºC. The lower muscular end was fixed in a 
phosphorbronze clip, and the upper tendinous end was attached to an electromagnetic 
length–tension transducer (University of Antwerp, Belgium). Preload was initially 
estimated according to muscle dimensions, varying between 3 and 4 mN. After 5 
minutes, muscles were stimulated at interstimulus interval of 1670 ms (which 
corresponds to a 0.6 Hz stimulation), with a voltage of 10% above threshold (typically 
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30-60 mV) by rectangular pulses of 5 ms duration through two platinum electrodes. Ten 
minutes later, bathing solutions were replaced by serum solution and the muscle 
started to contract. Eight minutes later, bathing solution was replaced by modified KR 
solution. During the next 15 to 30 minutes, the muscles stabilized. Finally, the muscles 
were stretched to a muscle length at which active force development was maximal. 
This length (mm) is known as maximum physiological length (Lmax). Protocols 
(described below) were initiated after obtaining two similar isotonic and isometric 
control twitches separated by a 5 min interval. During all time of protocols, baths were 
maintained at a constant temperature of 30°C and bubbled with 95% O2-5% CO2. At 
the end of the experiment, muscles were measured, weighed and immediately frozen 
in liquid nitrogen and stored in an -80ºC freezer until use for protein quantification by 
Western blot. Muscle cross-sectional area was calculated by dividing the weight of the 
muscle by its length at Lmax. A cylindrical shape and a specific gravity of 1.0 were 
assumed. Muscle tension was then expressed as force normalized per cross-sectional 
area (mNmm-2). All reagents were obtained from Sigma-Aldrich and Merk. Serum, BDM 
and modified Krebs solutions were used at a 7.36-7.42 pH range. 
 
 
 
 
 
 
 
 
4.1 Experimental protocols 
Rat papillary muscles from different groups (TAC, Sham, L-NAME and Ctrl) 
were subjected to increasing concentrations of Intermedin (IMD1-47; 10
-10 to 10-6 M) and 
effects of this peptide on myocardial contraction and relaxation parameters were 
analyzed. Those parameters include active tension (AT, mN.mm-2) and maximal 
velocities of tension rise (dT/dtmax, mN.mm-2.s-1) and decline (dT/dtmin, mN.mm-2.s-1). 
Once obtained a stable response, muscle twitches were recorded. Isotonic and 
isometric acquisitions were converted online to digital data with a sampling frequency 
of 1000 Hz (Daqbook/120, IOTech Inc. Cleveland, Ohio, USA) and analyzed with a 
dedicated software (University of Antwerp, Belgium). Results are given as percent 
change from baseline.  
Figure 16 – Simplified diagram of isolated papillary muscles setup. Isolated papillary muscle is shown in red. Its base 
is fixed at the bottom of a long rod while its top is connected to a force transducer (Dhein, 2005).  
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5. Western blot experiments 
In order to determine levels of total cTnI (t-cTnI), phosphorylated cTnI at 
Ser23/24 (p-cTnI), PLB, phosphorylated PLB at Ser-16 (p-PLB), total eNOS (t-eNOS) 
and phosphorylated eNOS at Ser-1177 (p-eNOS), a western blot analysis was 
performed in LV papillary muscles subjected to different conditions: a) without IMD 
(n=4, experiments performed 2 to 3 times) and b) with increasing concentrations of 
IMD (n=4, experiments performed 2 to 3 times). These samples were homogenized on 
ice in 1 ml radio-immunoprecipitation assay (RIPA) lysis buffer containing 
phenylmethylsulfonyl fluoride (1 mM), aprotonin (10 g/ml), leupeptin (10 µg/ml), and 
pepstatin (10 µg/ml) all from Sigma Chemicals (St. Louis, MO, USA) as the protease 
inhibitors. Then, samples were centrifuged at 14,000g for 20 min at 4 ºC, after which 
the supernatants were collected. Total protein content was determined using a Bio-Rad 
protein assay kit. Depending on protein, samples containing 30 µg or 10 µg of protein 
were loaded on a 6% for eNOS or 10 % for cTnI and 15% for PLB sodium dodecyl 
sulfate-polyacrylamide gel (SDS-PAGE), respectively, run and electroblotted onto 
polyvinylidene difluoride membrane. As molecular weight marker proteins, we used the 
Precision Plus Protein™ Dual Color standards (ref. 161-0374, Bio-Rad). In order to 
attest the quality of the transfer and to ensure equal protein content was loaded, a 
ponceau staining was done. 
The blocking of blots was performed by emerging membranes on 10% Bovine 
Serum Albumine (BSA) or 10% skimmed nonfat milk (both diluted in 0,1% TBST), 
depending on phosphorylation or non-phosphorylation of proteins, respectively, for 3 
hours under agitation. Then, membranes were incubated overnight at 4ºC with primary 
antibody (1:1000) against our target proteins: eNOS, ref. 9572S, Cell signalling; PLB, 
ref. ab85146, Abcam; cTnI, ref. 4002S, Cell signaling; β-actin, ref. 4967S, Cell 
signaling; p-eNOS, ref. 9571S, Cell signalling; p-PLB, ref. ab15000, Abcam; p-cTnI, ref. 
4004S, Cell signalling. After washing, they were incubated with alkaline phosphatase 
secondary antibodies (Anti-rabbit IgG, ref. 7054S, Cell signaling) for 1h at room 
temperature. Finally, chemifluorescent detection was performed by using an ECF 
Western blotting detection system (Amersham Biosciences). 
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6. Real-time reverse-transcription 
polymerase chain reaction (qRT-PCR) 1 
Total RNA content was extracted from samples using Tripure (Roche, 
Germany). Primers were designed for both GTPCH-1 and and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) rat sequences (Table 3). This latter is commonly 
used as internal control for qRT-PCRs since it was considered a housekeeping gene, 
i.e. its expression levels remains unaltered during the experience (Barber, Harmer et 
al., 2005). The reverse transcriptase used was the SuperScript II from Invitrogen; for 
real time reaction, it was used the PerfeCTa® SYBR® Green FastMix® (ROX™) kit 
from Quanta Biosciences. Both reactions were performed in a LightCycler 2.0 (Roche). 
For Real-time PCR, we followed the standard cycling, with an initial denaturation of 
95ºC (1 min) and a final extension of 60ºC (30seg); the cycle program used was 95ºC 
(15 seg) and 60ºC (10 seg). Both StepOne™ Software v2.2.2 and Microsoft Excel 
were used to analyze results of real time. The obtained values for GTPCH-1 were 
normalized for GAPDH gene by fold difference.   
 
 
Table 3 – Nucleotide sequences and melting temperatures (Tm) of specific primers used for real-time PCR. All 
sequences are represented on 5’3’ direction. 
 
 Forward Tm (ºC) Reverse Tm (ºC) 
GTPCH1 TGGAGAAGCCGCGGGGTGTA 63.6 AGTAAGCGGCCGCCAGGTTG 63 
GAPDH TGCCACTCAGAAGACTGTGG 59.6 GGATGCAGGGATGATGTTCT 57.4 
 
 
 
7. eNOS activity 
Conversion of L-arginine to L-citrulline in LV myocardial homogenates was used 
to determine eNOS activity (Stratagene, La Jolla, Calif, ref. 204500), as described 
previously by Moens et al (Moens, Takimoto et al., 2008). Firstly, LV samples were 
homogenized in a solution of Tris-HCl (250 mM, pH 7.4), EDTA (10 mM), and EGTA 
(10 mM) and spun at full speed for 5 minutes at 4°C. Supernatant was incubated in 
                                                          
1
 This experience was performed by Doctor Sónia Pinho, from the Cardiovascular Research & Development Unit, Faculty of Medicine, University of Porto. 
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NADPH (10 mM), L-[3H]arginine (ref. NET1123250UC, from Perken Elmer; 1 mCi/mL), 
CaCl2 (6 mM), Tris-HCl (50 mM; pH 7.4), BH4 (6 µM), flavin adenine dinucleotide (2 
µM) and flavin mononucleotide (2 µM) for 60 minutes at 24°C. According kit 
manufacturer, this reaction finished with HEPES (50 mM; pH 5.5), EDTA (5 mM) and 
equilibrated resin (this resin binds to arginine). This solution was then transferred into a 
spin cup and spun at full speed for 30 seconds. By liquid scintillation counting, it was 
possible to determine the supernatant radioactivity, which represents L-citrulline. 
Finally, in order to determine the unreacted arginine/L-citrulline ratio, 400 μl of elution 
buffer were added to the spin cup, which was then transferred to a microcentrifuge tube 
and spun at full speed for 30 seconds. Enzyme activity was expressed as L-citrulline 
production in pmol/(mg of protein)/h. 
 
 
8. Quantification of nitrotyrosine 
In order to determine levels of nitrotyrosine (a biomarker of ONOO- formation) in 
the LV myocardial samples, protein nitration was estimated using 
immunohistochemical methods.  Initially, 6 µm LV sections were washed with 
phosphate-buffered saline (PBS) and fixed in ice cold pure acetone for 10 min. Their 
permeabilization was achieved by their incubation for 10 min, in a pH 7.4 solution 
containing PBS and 1% Triton X-100. Then, they were blocked with 10% goat serum, 
for 30 min, at room temperature. Sections were incubated overnight at 4ºC with primary 
antibodies against nitrotyrosine, which were diluted in PBS and 0,2% BSA. Prior 
incubation for 1h at room temperature with second antibodies (diluted similarly to the 
primary antibodies), sections were washed with a PBS and 0.2% BSA solution. 
Sections were again washed and incubated with the 2µM 4',6-diamidino-2-phenylindole 
(DAPI) for 30 min, at 37ºC. After washing, sections were fixed in 4% paraformaldehyde 
for 10 min. Preparations were then washed, dried and mounted with Glycergel Dako 
mounting medium (Dako, Carpinteria, CA, USA). Immunostained sections were finally 
visualized with a Leica DMIRE200 fluorescence microscope, whose settings remained 
constant. Fluorescence was quantified using Image (1.40g, NIH). 
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9.  Chemicals and solutions 
All chemicals were obtained from Sigma Chemical Co, St Louis, with the 
exception of: IMD, which corresponds to the active form of 47 amino-acid (IMD1-47), that 
was obtained from Bachem (Bubendorf, Switzerland); eNOS activity kit, obtained from 
Stratagene (La Jolla, California, USA); [3H]-arginine, obtained from Perken Elmer 
(Massachusetts, USA). Antibodies anti-eNOS and anti-cTnI were obtained from Cell 
Signaling Technology Inc., (Massachusetts, USA) and antibodies anti-PLB were 
obtained from Abcam (Cambridge, UK). The stock solutions, including IMD, were 
prepared in distilled water and stored as frozen aliquots at -20ºC until use.  
 
 
 
10. Statistical analysis 
GraphPad Prism 5.0 software was used for data analysis. Values are presented 
as mean ± standard error of mean (SEM) and n represents the number of animals or 
papillary muscles. Differences in treatment effects among the different animal groups 
were evaluated using a two-way ANOVA. When significant differences were detected 
with any of the ANOVA tests, the Dunnet test was selected to perform pairwise multiple 
comparisons, with P<0.05 being considered significant. In all other experiments, 
statistical significance was assessed using a two-tailed Student's unpaired t test with 
P<0.05 being considered significant. 
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III. Results 
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1. Characterization of animal models 
In order to characterize the animal models, we performed morphometric and 
hemodynamic measures, which are summarized in Table 4. Both TAC and L-NAME 
animals presented a significant increase in heart weight/body weight ratio, compared to 
their respective controls (Sham and Ctrl). These results suggest TAC and L-NAME 
animals developed LV hypertrophy. Similarly, left ventricular systolic pressure (LVSP) 
is significantly increased in those models relatively to their controls; however a 
significantly higher left ventricular end-diastolic pressure (LVEDP) was recorded just in 
the TAC animals. Furthermore, these animals showed a slower left ventricular 
relaxation, suggested by a greater tau value.  
 
 
Table 4 – Summary of morphometric (7-8 animals) and hemodynamic (4-7 animals) measures performed in Sham, 
TAC, Ctrl and L-NAME animals. All data are presented as mean SEM (standard error mean). HW means heart weight; 
BW means body weigh; LVSP means left ventricular systolic pressure; LVEDP means left ventricular end-diastolic 
pressure; dPdt max means maximum velocity of pressure rise; dPdt min means maximum velocity of pressure decline;  
  means tau. * P<0.05 vs Sham; #P<0.05 vs Ctrl.  
 
 Sham TAC Ctrl L-NAME 
HW/BW  
(g/kg) 
2.9±0.1 3.4±0.2* 2.3±0.1 2.7±0.2# 
Heart Rate  
(bpm) 
403±11 386±17 410±19 378±21 
LVSP  
(mmHg) 
120±5 158±9* 110±3 147±12# 
LVEDP  
(mmHg) 
4.0±0.4 10.0±2.0* 3.7±0.4 5.6±1.0 
dPdt max 
(mmHg/sec) 
7559±143 7234±629 6612±430 7131±900 
dPdt min 
(mmHg/sec) 
-9436±474 -8065±948 -8714±2 -9382±1583 
  8±0.3 12±1.0* 9±2.0 10±1.0 
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2. Effect of IMD on contractile and 
relaxation parameters  
Before the beginning of IMD protocol, contractile parameters of stabilized left 
ventricular papilary muscles were recorded and are summarized in Table 5. Results 
indicate there are not any statistical differences between the different animal models 
except for time to half relaxation (tHR), which is significantly higher in L-NAME animals. 
This particular result was already expected since it is known NO promotes hastening of 
relaxation (Paulus, Vantrimpont et al., 1994).  
 
 
Table 5 – Summary of contractile and relaxation parameters at baseline of LV papillary muscles from the different 
animal models. All data are presented as mean SEM (standard error mean). AT means active tension; dT/dtmax 
means maximum velocity of tension rise; dT/dtmin means maximum velocity of tension decline; PS means passive 
tension; dL/dtmax means maximum velocity of shortening; dL/dtmin means maximum velocity of lengthening; tHR 
means time to half relaxation. 
#
P<0.05 vs Ctrl.   
 
 Sham 
(n=6) 
TAC 
(n=7) 
Ctrl 
(n=6) 
L-NAME 
(n=5) 
AT 
(mN/mm2) 
15±2 16±4 18±3 23±8 
dT/dtmax 
(mN/mm2/sec) 
141±35 198±53 199±20 230±81 
dT/dtmin 
(mN/mm2/sec) -71±10 -99±20 -112±9 -115±39 
PS 
(%Lmax) 0.1±0.01 0.08±0.01 0.08±0.01 0.1±0.01 
dL/dtmax 
(Lmax/sec) 1.5±0.1 1±0.1 1±0.1 1±0.1 
dL/dtmin 
(Lmax/sec) -1.7±0.3 -1.3±0.2 -1.2±0.2 -1.2±0.2 
tHR 
(msec) 292±34 257±16 265±21 318±19
#
 
 
Concerning IMD protocols, we verified that IMD addition in LV papillary muscles from 
Sham and Ctrl rats induced a similar decrease in AT (11±5% and 12±4%, respectively) 
and dT/dtmax (5±4% and 7±4%, respectively) while relaxation parameters did not 
present any statistical changes (Figure 17, A, B and C). On the other hand, in left 
ventricular papillary muscles from TAC and L-NAME rats, IMD induced an increase of 
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AT (11±3% and 13±3%, respectively) and dT/dtmax (20±3% in both). Furthermore, in 
these animal groups, IMD induced an increase in the rate of relaxation (dT/dtmin; 
23±4% and 31±6%, TAC and L-NAME rats respectively), suggesting an hastening 
effect on relaxation. In short, these data showed a different IMD myocardial effect, 
promoting a negative inotropic effect in both control groups (Sham and Ctrl) but the 
opposite effect in TAC and L-NAME rats, in which it induced a positive inotropic and 
lusitropic effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 17 – Effect of increasing concentrations (10-10 to 10-6) of IMD on isolated left ventricular papillary muscles from Sham (n=6), 
TAC (n= 7), Ctrl (n= 6) and L-NAME (n= 5) rats, in A) Active Tension (AT), B) maximum velocity of tension rise (dT/dtmax) and C) 
maximum velocity of tension decline (dT/dtmin). *P<0.05 vs Sham; 
#
P<0.05 vs Ctrl.   
A B 
C 
#  * #  * 
#  * 
#  * 
#  * 
#  * 
#  * 
#  * 
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3. Cardiac endothelial dysfunction in TAC rats 
Since IMD has an eNOS-mediated effect on myocardium, and so it is 
dependent on NO bioavailability (Pires, Pinho et al., 2012), we searched for endothelial 
dysfunction in LV hipertrophy rat models (Figure 18).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18– Search for endotelial dysfunction on left ventricle hipertrophy animal models. A) Western blot analysis of 
expression of  total eNOS (t-eNOS), normalized to beta-actin (β-actin), whose graphic representation shows a 
statistical similarity between Sham and TAC rats. B) Immunohistochemical staining of left ventricle samples from 
Sham, Ctrl, TAC and L-NAME rats (n= 5-6). The graphic representation shows both TAC and L-NAME rats have an 
increased level of nitrotyrosine relatively to their respective controls, Sham and Ctrl. C) GTPCH-1 mRNA expression 
in Sham and TAC rats, whose levels are statistically similar in both groups. D) Levels of conversion of L-arginine to L-
citruline, which are significantly greater in Sham rats than in TAC rats, suggesting a diminished eNOS activity in these 
latter. *P<0.05 vs Sham; 
#
P<0.05 vs Ctrl.  
A 
C 
B 
# 
* 
D 
* 
140 KDa 
45 KDa 
TAC 
L-NAME 
S
C
Sham 
Ctrl 
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To do that, we started by accessing eNOS protein expression in TAC rats, 
which was statiscally similar to that in Sham rats (Figure 18A). Since oxidative stress is 
a main cause of endothelial dysfunction, we immunohistochemically stained left 
ventricle samples from all animal models to detect nytrotirosine, whose levels were 
increased in TAC and L-NAME rats (Figure 18B), suggesting the presence of high 
levels of ONOO-, a resultant product of reaction between superoxide and NO. On the 
other hand, decrease of BH4 is another possible cause for eNOS uncoupling so we 
investigated transcript levels of GTPCH1, whose expression translates in production of 
the rate-limiting enzyme of de novo synthesis of BH4. However, those transcript levels 
are not statistically different in TAC model (Figure 18C), indicating that BH4 production 
is unchanged. Despite that, TAC rats presented a lower conversion of L-arginine into L-
citruline, showing a diminished baseline eNOS activity, relatively to Sham rats (Figure 
18D). 
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4. Activation of eNOS by IMD1-47 
Phosphorylation of eNOS at Ser-1177, which is associated with activation of 
eNOS, is statistically greater in TAC rats when compared with Sham rats, at baseline 
(Figure 19A). In papillary muscles from Sham rats, IMD addition tripled the eNOS 
phosphorylation levels, while in those from TAC rats IMD addition was not able to 
enhance those levels (Figure 19A). A similar trend was observed in papillary muscles 
from Ctrl and L-NAME rats (Figure 19B). Thus, in TAC and L-NAME rats, there is an 
impairment of IMD-induced eNOS activation, since IMD is not able to increase baseline 
levels of phosphorylated eNOS in those animal models.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. IMD treatment-induced phosphorylation of 
regulatory proteins  
 
According with our previous report (Pires, Pinho et al., 2012), addition of IMD 
increasing concentrations in papillary muscles from Sham and Ctrl rats increased c-TnI 
phosphorylation relatively to those muscles without IMD addition (Figure 20, A and C). 
However, IMD treatment in TAC and L-NAME rats had no statistical effect in p-cTnI 
* 
* 
Figure 19 – Western blot analysis of phosphorylated eNOS at Ser-1177 (p-eNOS) and total eNOS (t-eNOS) levels in 
papillary muscles from A) Sham and TAC rats and B) Ctrl and L-NAME rats. Papillary muscles from Sham and Ctrl 
rats showed increasing levels of p-eNOS upon IMD addition (IMD) relatively baseline levels (control), while in TAC 
and L-NAME rats IMD addition failed to increase those levels. *P<0.05 vs Sham control; 
#
P<0.05 vs Ctrl control.   
A B 
# 
# 
* 
* 
140 KDa 
140 KDa 
45 KDa 
140 KDa 
140 KDa 
45 KDa 
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levels (Figure 20, A and C). Concerning p-PLB, its levels increased in both L-NAME 
and TAC rats but it was statistically significant only in these latter (Figure 20, B and D). 
These results suggest that IMD activates different signalling pathways in control and 
pressure-overloaded animal models, with phosphorylation of different proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – Western blot analysis of phosphorylated cardiac troponin I (p-cTnI) and phosphorylated phospholambam 
(p-PLB) in papillary muscles from Sham and TAC rats (A and B) and Ctrl and L-NAME rats (C and D), without 
(control) and with IMD addition (IMD). Upon IMD addition, in both Sham and Ctrl rats, cTnI phosphorylation increased, 
while in TAC (A) and L-NAME (C) rats this effect was blunted. Concerning p-PLB, statistical increasing was found only 
in TAC rats upon IMD addition (B), despite a similar trend is verified in L-NAME rats (D). *P<0.05 vs Sham control; 
**P<0.05 vs TAC control; 
#
P<0.05 vs Ctrl control.   
A B 
* 
** 
C D 
# 
28 KDa 
28 KDa 
6 KDa 
6 KDa 
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IV. Discussion 
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1. TAC and L-NAME: two distinct animal 
models 
In the present study, results show that either transverse aorta constriction or L-
NAME oral administration are able to induce LV hypertrophy and increased LVSP. 
These data are in accordance with previous studies, which reported these two 
sequential events in both TAC (Scopacasa, Teixeira et al., 2003) and L-NAME 
(Nguelefack, Mekhfi et al., 2009) models. However, only the TAC rats presented a 
significant increase in LVEDP and tau haemodynamic parameters, which are also in 
agreement with previous data (Yu, Ruifrok et al., 2013). All these haemodynamic 
alterations have not a great impact in LV contractile parameters from both TAC and L-
NAME groups, except the tHR. This parameter is statistically increased only in L-NAME 
rats, where the blocking of NO production is responsible for this slow relaxation, as we 
expected (Gasheva, Zawieja et al., 2006).   
Despite these similarities, TAC and L-NAME groups are very different, 
immediately by the fact that the pressure overload is achieved through different 
mechanisms. While TAC model is recognized as the best pressure overload model 
since it mimics the heart failure development in humans (Patten and Hall-Porter, 2009), 
L-NAME model raises some relevant questions. One of them relates to the fact that 
oral administration of L-NAME blocks all isoforms of NOSs (nNOS, iNOS and eNOS), 
therefore precluding NO production in whole organism, non-targeting a specific organ. 
Since these isoforms are spread to several different tissues (Bredt, 1999), their 
blocking will culminate in different effects. Accordingly, in addition to increasing of 
systolic blood pressure (Zicha, Pechanova et al., 2003) and cardiac hypertrophy 
(Nguelefack, Mekhfi et al., 2009), there are described other effects such as renal failure 
(Kung, Moreau et al., 1995) and other several forms of organ damage (Kopincova, 
Puzserova et al., 2012), hypertension (Johnson and Freeman, 1992) and pronounced 
alterations of endothelium and vascular smooth muscle of the aorta (Kung, Moreau et 
al., 1995). Evidence refers that long-term effects of L-NAME are mediated by other 
mechanisms and not only by NOS inhibition (Suda, Tsutsui et al., 2002). Besides, 
these effects depend on the concentration of administered L-NAME, the duration of 
treatment and the way of L-NAME administration, being reported multiple studies which 
differ precisely in these variables (Kopincova, Puzserova et al., 2012). Even so, 
reported data have been controversial namely concerning LV hypertrophy, since for 
example by using 20mg/kg/day (Pechanova, Bernatova et al., 1999b) and 50mg/kg/day 
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(Arnal, Warin et al., 1992) for 4 weeks, authors obtained presence and absence of 
hypertrophy, respectively. In addition, while myocardial fibrosis seems to be positively 
dose-dependent (Pechanova, Bernatova et al., 1999a), systolic blood pressure is 
believed to be dose-independent (Pechanova, Bernatova et al., 1999b). Despite this, 
we decided to administrate L-NAME at a concentration of 35mg/kg/day for 10 weeks, 
since Zhao et al refer it as a suitable dose for establishing of a cardiac remodeling 
model induced by long-term NOS inhibition (Zhao, Bell et al., 2006).     
With all this in mind, we discuss our results below. 
 
2. Role of eNOS in diseased heart models 
Recent evidence has suggested NO plays an important and central role in heart 
failure pathogenesis (Akiyama, Sugiyama et al., 2012). At the cardiovascular level, its 
main source is eNOS (Dudzinski, Igarashi et al., 2006) and its low bioavailability is 
intimately associated to endothelial dysfunction (Lam and Brutsaert, 2012). In addition 
to endothelial dysfunction, oxidative stress was also identified as a main cause for 
heart failure, in a joint process which results in eNOS uncoupling and further increases 
of oxidative stress (Marti, Gheorghiade et al., 2012). Since IMD myocardial effects 
depend on NO production by endothelium in Sham rats (Pires, Pinho et al., 2012), we 
evaluated endothelial function in TAC rats in order to know whether this dysfunction 
could explain the different response obtained in both Sham and TAC rat models. We 
did not perform a similar analysis for L-NAME rats since this model results from a 
chronic and generalized blockage of NO production. So, we investigated whether LV 
hypertrophy rat model (TAC) presented some hint of endothelial dysfunction.  
Our results indicated expression of eNOS is not altered, despite previously 
Loyer et al have reported a significant increase in that expression in female TAC rats 
(Loyer, Damy et al., 2007). Although gender difference could explain this different 
eNOS expression, this possibility is poorly supported by evidence (Sullivan, Pardieck et 
al., 2010). Indeed, our result are in accordance with previous studies which reported 
the maintenance or even the increasing of eNOS expression levels under endothelial 
dysfunction conditions (Channon, 2004). Despite not being intuitive, this result is 
explained by the fact that this augmentation of eNOS expression is not accompanied 
by a similar behaviour of BH4 levels, generating an imbalance. This disequilibrium allied 
with a low BH4/ BH2 ratio, which is another key determinant of eNOS uncoupling 
(Crabtree, Tatham et al., 2009), resulting in endothelial dysfunction. However, in our 
 
FCUP 
Myocardial effect of Intermedin in hypertrophic heart:                                                                                    
mechanisms and involvement of endothelial dysfunction 
44 
 
work, BH4 de novo synthesis seems not to be altered since GTPCH1 mRNA expression 
remained unchanged.  
At the protein level, eNOS activity can be modulated by different manners. One 
of them is reduction of L-arginine content (Kietadisorn, Juni et al., 2012), which could 
explain the decreased conversion rate of L-arginine to L-citrulline that we verified. 
Therefore, this result suggests a decreasing of eNOS activity. Another group of 
determinants include post-translational modifications of eNOS, which are able to 
modulate eNOS activity and are tightly associated with subcellular localization of eNOS 
(Dudzinski and Michel, 2007). These modifications include phosphorylation (Mount, 
Kemp et al., 2007), S-nitrosylation (Ravi, Brennan et al., 2004), palmitoylation (Wang, 
Wang et al., 2009), acylation (Shaul, Smart et al., 1996), S-glutathionylation (Chen, 
Wang et al., 2010) and binding of CaM (Presta, Liu et al., 1997). Particularly, eNOS 
contains some sites susceptible to phosphorylation namely Ser-1177, which is 
augmented at the baseline in both L-NAME and TAC rats – this latter result is in 
accordance with a previous report (Moens, Leyton-Mange et al., 2009). Since this 
modification promotes increasing of eNOS activity (Rafikov, Fonseca et al., 2011), 
these results are contradictory with our observation about conversion of L-arginine to L-
citrulline, as also reported by Moens et al in TAC mice (Moens, Leyton-Mange et al., 
2009). The phosphorylation of Ser-1177 was previously reported as a result from direct 
phosphorylation by Akt, leading to an increase in NO production by endothelial cells 
(Fulton, Gratton et al., 1999). Despite having other regulatory proteins such as PKA 
and AMPK (Giustiniani, Couloubaly et al., 2009), Ser-1177 phosphorylation seems to 
be mainly controlled by Akt activation, since this latter has been increasingly implicated 
in several important cellular mechanisms, including endothelial NO production (Chen, 
Druhan et al., 2008; Yoshitomi, Xu et al., 2011). Accordingly, it was reported an 
enhanced Akt activity in TAC mice (Naga Prasad, Esposito et al., 2000), which 
reinforces this putative preponderant role of Akt in HF. On the other hand, high levels 
of nitrotyrosine were obtained in myocardium samples from both TAC and L-NAME 
rats, suggesting an increased oxidative/nitrosative stress. Under these conditions, 
eNOS suffers an enzymatic turnover, starting to produce ●O2
- instead of NO (Moens 
and Kass, 2006) (Figure 21). Production of NO is thought to be carried out by nNOS 
(Niu, Watts et al., 2012); accordingly, evidence suggests nNOS expression levels are 
enhanced in HF although evidence is not consensual (Damy, Ratajczak et al., 2003; 
Damy, Ratajczak et al., 2004; Danson, Choate et al., 2005). Besides, the reaction of 
●O2
- with free radical NO results in ONOO- production (Pacher, Beckman et al., 2007). 
This event reduces BH4 bioavailability by its oxidation into BH2 (Kietadisorn, Juni et al., 
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2012) and consequently there is an augmentation of oxidative/nitrosative stress as 
explained in Figure 22. Moreover, Chen et al reported that these BH4 depletion 
conditions allied to  eNOS Ser-1177 phosphorylation greatly enhances eNOS-mediated 
●O2
- generation (Chen, Druhan et al., 2008). Taken together, these results and reports 
suggest that there is a chronic activation of Akt in TAC rats which promotes 
phosphorylation of Ser-1177 in eNOS. This phosphorylation, in turn, is not efficient 
since, contrary to what was expected, we verified a decreasing of eNOS “normal” 
activity, with concomitant decrease in NO production. Furthermore, and given the 
cellular oxidative environment and the enzymatic turnover of eNOS, generation of ●O2
- 
by eNOS also increases, i.e., in TAC rats eNOS Ser-1177 phosphorylation enhances 
“pathologic” activity of eNOS. Our results further emphasize that analysis of eNOS 
phosphorylation at Ser-1177 site is not per se sufficient to draw conclusions about 
eNOS “normal” activity (Fleming, Fisslthaler et al., 2001). Indeed, eNOS has other sites 
susceptible to be phosphorylated (Mount, Kemp et al., 2007) and further studies are 
necessary in order to clarify effects of phosphorylation of some of those sites as well as 
their hypothetical crosstalk and relationship to other systems of eNOS activity 
modulation (Mount, Kemp et al., 2007; Rafikov, Fonseca et al., 2011), also taking into 
account the cellular environment and experimental conditions.  
 
 
 
Figure 21 –  Bioavailability of BH4 affects eNOS activity. Under physiological conditions (A), BH4, NADPH, FMN, FAD 
and CaM allow production of L-citrulline and NO, from L-arginine and molecular oxygen. However, when BH4 
bioavailability is decreased (B), eNOS suffers an enzymatic turnover, leading to 
●
O2
-
 production instead of NO and there 
is no L-citrulline generation. From Chanon (Channon, 2004).   
A 
B 
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Regarding to L-NAME rats, eNOS is blocked so there is no NO production or a 
poorly production. Despite being referred as a NO and ●O2
- generation blocker (Chen, 
Druhan et al., 2008), L-NAME was able to induce increase of oxidative/nitrosative 
stress through induction of ●O2
- production (Usui, Egashira et al., 1999). This suggests 
eNOS is not the only source of ROS, which is in accordance with previous studies 
which reported ROS generation by mitochondria under physiologic conditions (Abel 
and Doenst, 2011). According to the same authors, under pathological conditions 
extra-mitochondrial sources, mainly NADPH oxidases (Kuroda, Ago et al., 2010), are 
responsible for ROS production. These, in turn, will induce mitochondrial uncoupling, 
whose role in pressure overload cardiac hypertrophy is not still completely understood 
(Abel and Doenst, 2011).  
 
 
 
Figure 22 – eNOS-derived NO reacts with ●O2
-
, resulting in ONOO- production. This, in turn, diminishes BH4 
bioavailability by oxidation into BH2. Under this BH4 depletion conditions, eNOS starts to produce 
●
O2
- 
instead of NO, 
contributing for increase of oxidative stress which, in turn, worsens eNOS function and reacts with NO, in a vicious 
cycle. Adapted from Forstermann et al (Forstermann and Munzel, 2006).    
  
 
In addition, interaction between eNOS and other proteins is able to modulate 
activity of eNOS, thus regulate NO production. For instance, increasing of interaction 
between eNOS and caveolin-1 (cav-1) diminishes NO production, whereas heat shock 
protein-90 (Hsp90) is required for eNOS activation through Ser-1177 phosphorylation 
(Davignon and Ganz, 2004).  
To sum up, both models present endothelial dysfunction due to decreased NO 
bioavailability, despite their differences. Phosphorylation of eNOS at Ser-1177 seems 
to play an important role in eNOS activity, hence in endothelial function. Therefore, we 
NADPH oxidase 
eNOS 
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reinforced the idea that eNOS plays an important and crucial role in pressure-
overloaded hearts, in particular, but in failing hearts, in general.   
 
3. IMD myocardial effects 
Our results showed IMD promoted a significant increase of eNOS Ser-1177 
phosphorylation in both control groups (Sham and Ctrl) while in disease heart models 
(TAC and L-NAME) it was not able to trigger a similar effect. Assuming that these latter 
groups present a chronic activation of Akt/PKB, then IMD is not able to further increase 
these levels of eNOS phosphorylation. Thus, we are assuming the existence of a 
hypothetical but likely maximum limit for the ratio peNOS/teNOS and at the same time 
an intrinsic limit of IMD action which has a maximal power to phosphorylate eNOS. 
Similarly to eNOS, upon IMD addition, cTnI phosphorylation increases only in control 
groups, while phosphorylated PLB levels were increased only in disease models. We 
hypothesize that under physiologic conditions IMD activates both AM and CGRP 
receptors (Pires, Pinho et al., 2012), promoting Akt-mediated activation of eNOS 
through its phosphorylation on Ser-1177 site, resulting in augmentation of NO 
production. Next, this gas disseminates from endocardial endothelial cells into 
cardiomyocytes, activating soluble guanylate cyclase (sGC) thus promoting cGMP 
synthesis and PKG activation and leading to increasing of phosphorylation of cTnI Ser-
23/24 site (Layland, Solaro et al., 2005). This modification reduces myofilament Ca2+ 
sensitivity (Layland, Li et al., 2002) and avoids the binding of myosin to actin, resulting 
in a negative inotropic effect (Layland, Solaro et al., 2005) (Figure 23).  
On the other hand, under pathological conditions, we hypothesize that IMD 
preferentially activates CGRP receptor (Pires, Pinho et al., 2012). Since there is a low 
bioavailability and reduced production of NO due to endothelial dysfunction and 
increased oxidative/nitrosative stress, IMD directly activates the cAMP/PKA pathway. 
As a result, PKA promotes phosphorylation of PLB at Ser-16; this modification allows  
PLB releasing from SERCA complex, removing PLB inhibitory effect (Glaves, Trieber et 
al., 2011). The consequent augmented SR Ca2+ uptake results in a dramatic and fast 
decreasing of Ca2+ cytoplasmic content, which in turn leads to an increasing of both 
contractility (active tension) and relaxation (maximum velocity of tension decline) of 
cardiomyocytes, as previously described (MacLennan and Kranias, 2003; Zhang, Yu et 
al., 2011). These effects are called positive inotropic and lusitropic effects. In addition, 
PKA is also able to phosphorylate LTCC, reversing the basal inhibition, increasing Ca2+ 
cellular influx and loading and release of SR Ca2+ (Zipes and Jalife, 2009) and thus 
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contributing to elevation of both active tension and maximum velocity of force 
generation (Figure 23). Interestingly, in HF rats, velocity of force generation is 
decreased due to both downregulation of α-MHC (myosin heavy chain) and 
upregulation of β-MHC mRNA expression levels (Huang, Liu et al., 2001). Therefore, 
IMD seems to play an important role at MHC expression levels, reversing α/β ratio and 
contributing for increasing of force generation velocity.  
In addition, particularly in TAC rats, we cannot exclude the involvement of 
neurohumoral activation-related mechanisms, since progression of heart failure is 
intimately associated with neurohumoral activation (Middlekauff and Mark, 1998), 
namely increasing of plasma catecholamines levels (Viquerat, Daly et al., 1985). This 
releasing results in a chronic catecholamine stress, which leads to a desensitization 
and downregulation of β1-AR and β2-AR/adenylyl cyclase signaling pathway 
(Okumura, Vatner et al., 2007), accompanied with upregulation of β3-AR (Moniotte, 
Kobzik et al., 2001; Morimoto, Hasegawa et al., 2004; Zhao, Wu et al., 2007), which 
mediates a NO-dependent negative inotropic effect (Gauthier, Leblais et al., 1998). 
However, it seems IMD elicits activation of both β1 and β2-ARs, which are able to 
induce cAMP/PKA pathway, leading to phosphorylation of LTCC (Kamp and Hell, 
2000). This modification promotes the Ca2+ entering on the cell (Zipes and Jalife, 2009), 
contributing to the positive inotropic effect (by enhancing active tension) and to the 
increasing of velocity of tension rise. Also the involvement of cyclic nucleotide 
phosphodiesterases (PDEs) cannot be excluded since there are 11 mammalian PDE 
families responsible for specific cAMP and/or cGMP hydrolysis (Omori and Kotera, 
2007). Some of them are reported as playing important role in heart failure: for 
example, PDE3A expression is decreased in human samples (Ding, Abe et al., 2005) 
while PDE5 inhibition is not only prescribed for treatment of erectile dysfunction and 
pulmonary hypertension (Kumar, Francis et al., 2009) but recently also for therapeutic 
management of HF (Guazzi, 2008). Concerning L-NAME rats, phosphorylation of PLB 
presents a positive trend, however it was not statistically significant. This result 
suggests there are other possible regulatory proteins involved, so more researches are 
needed. Therefore, we are aware that cascade of events which mediates IMD 
myocardial effects in pressure-overload rats is much more complex. Nevertheless, we 
constructed Figure 23 where we include both our results and what is already known 
from literature, creating a simple illustration with what we think that is the most likely 
sequence of events which leads to IMD myocardial effects, under physiologic and 
pathophysiologic conditions.  
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Figure 23 – Cascade of events which mediated myocardial effects of IMD both under physiological (A) and pathophysiological (B) conditions. In presence of NO (A), cGMP/PKG signaling pathway 
is activated, resulting in phosphorylation of cTnI, decrease of myofilament  Ca
2+
-sensitivity and thereby negative inotropic effect. On the other hand, in presence of endothelial dysfunction (B) there is 
no NO production, thus IMD directly activates cAMP/PKA signaling pathway, leading to positive inotropic and lusitropic effects mediated by phosphorylation of PLB and increase of SR Ca
2+
 uptake. 
This figure was done using Servier Medical Art.     
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The present work provides new insights about the myocardial effects of IMD 
and mechanisms behind these effects, in pressure-overload-induced HF. Besides, the 
study of involvement of cardiac endothelial dysfunction in those effects point IMD as a 
potential marker of cardiac endothelial dysfunction.    
 
Firstly, haemodynamic and morphometric analysis showed that the two disease 
models TAC and L-NAME are quite similar, with both showing LV hypertrophy and a 
preserved systolic function. Concerning contractile and relaxation parameters at the 
baseline, also both models did not present any statistical difference, except for tau 
which was increased in L-NAME, as we expected. Despite these similarities, for the 
subsequent analysis, we took into account differences between the two models, since 
pressure-overload is obtained through very different ways: one by aortic constriction 
(TAC), the other one by systemic hypertension (L-NAME).  
Next, administration of IMD in LV papillary muscles from the four different 
animal groups showed, for the first time, that IMD elicits two completely opposite 
effects: in diseased myocardium it promotes positive inotropic and lusitropic effects, 
whereas in normal myocardium data suggests a decrease of inotropy. This observation 
emphasizes the putative cardioprotective role of IMD in HF.  
One of the reasons which could explain these so different behaviors is 
endothelial dysfunction, since IMD myocardial effects are mediated by endothelium and 
HF is associated to its dysfunction. Despite eNOS expression was unchanged at the 
baseline, activity assay showed eNOS function was diminished. This fact allied to the 
presence of oxidative stress suggests eNOS uncouling thus endothelial dysfunction, 
which is not due to the depletion of BH4 but probably is partly due to a decrease of its 
bioavailability, since GTPCH1 expression remains unaltered. Interestingly, we verified 
phosphorylation of eNOS at Ser-1177 was augmented at the baseline in diseased 
myocardium and IMD was not able to increase those levels, contrary to what we 
observed in normal myocardium. We hypothesize this increased phosphorylation levels 
are likely due to Akt chronic activation. Taken together, results suggest that 
phosphorylation of eNOS at Ser-1177 1) is a great contributor for endothelial 
dysfunction in TAC rats, by promoting the “pathologic” activity of eNOS and 2) explains 
the opposite myocardial effects of IMD.  
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Finally, and based on expression results for regulatory proteins, we hypothesize 
IMD effects are mediated by 1) activation of cAMP/PKA signaling pathway and 
increase of phosphorylation of cTnI, in diseased myocardium and  2) NO-dependent 
activation of cGMP/PKG signaling pathway and increase of phosphorylation of PLB, in 
normal myocardium. Since IMD administration elicits different effects which are 
mediated by distinct mechanisms, this work also suggest that 1) endothelial 
dysfunction plays a central role in pathophysiology of HF and 2) IMD is a potential 
marker of cardiac endothelial dysfunction.    
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VI. Future 
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This work provides new insights about myocardial effects of intermedin and 
signaling pathways involved, reinforcing its putative cardioprotective role in 
cardiovascular disease. However, more studies are needed in order to prove this 
hypothesis. Firstly, it would be interesting draw a protocol for IMD chronic 
administration on chronic pressure-overloaded rats, namely in TAC model, since it is 
the most closer model of human HF. Recently, IMD chronic administration was done in 
SHR model and results seem to be very promising (Yuan, Wang et al., 2012).  
Another interesting topic would be to investigate the role of other post-
translational modifications of eNOS such as S-glutathionylation in HF. Indeed, recently 
Chen et al showed that under oxidative stress eNOS is S-glutathionylated in 
endothelial cells and this modification is responsible for production of ●O2
- by eNOS 
(Chen, Wang et al., 2010).    
Given the importance of study of heart failure, many authors have investigated 
different players in this so complex cardiac dysfunction. One of those players is 
oxidative stress. Contrary to expected, treatments using antioxidants have shown no 
clinical benefits (Hennekens, Buring et al., 1996; Yusuf, Dagenais et al., 2000). For this 
reason, studies have focus on sources of ROS: eNOS recoupling and increase 
endogenous levels of antioxidants are potential solutions (Takimoto and Kass, 2007). 
One of these studies recoupled eNOS through administration of both BH4 and 
apocynin, an inhibitor of NADPH oxidases, but the study was performed only in 
hypertensive aortas (Cai, Laude et al., 2006).       
Finally, in my opinion, the most interesting study line is miRNAs. Several 
miRNAs have been identified as important modulators of cardiovascular development 
and cardiac disease and have emerged as a good alternative for drugs (Small and 
Olson, 2011).  However, crosstalk of many miRNAs is poorly studied, which is an 
important obstacle for therapeutics, since silencing of one miRNA could be no effective. 
Besides, a miRNA has no only one target, so it is very important study and identify 
specific miRNAs.  
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